Lisa Stefany's Archive

info@myelomabeacon.com

 Lisa is currently a Junior English major in the Schreyer Honors College at Penn State University. She is pursuing a minor in Business in the Liberal Arts. Lisa joined The Myeloma Beacon as a writer and editor in the fall of 2009 and hopes to continue writing or editing for a print or Internet health magazine after graduation. Lisa is from Lansdale, Pennsylvania, and in her spare time, she loves to run, do yoga, read, hang out with friends, and root for all Penn State teams.

Lisa Stefany has written 5 article(s).

Beacon NewsFlashes – March 23, 2010
[ by Lisa Stefany | Mar 23, 2010 12:12 pm | No Comments ]
Beacon NewsFlashes – March 23, 2010

CyDex Begins Dosing Of CDX-353 In Phase 2 Trial For Myeloma Patients – Cydex Pharmaceuticals announced yesterday that it is initiating patient dosing in its Phase 2 trial of Propylene Glycol-Free Melphalan HCL (CDX-353), the company’s new form of melphalan (Alkeran). The trial compares CDX-353 with GlaxoSmithKline’s Alkeran in multiple myeloma patients who will be undergoing stem cell transplants (see related Beacon news).  For more information, please see the CyDex press release and the clinical trial…

Read the full story »
Beacon NewsFlashes – February 18, 2010
[ by Lisa Stefany | Feb 18, 2010 3:17 pm | No Comments ]
Beacon NewsFlashes – February 18, 2010

Dacetuzumab Shows Some Potential For Multiple Myeloma – Results from a Phase 1 clinical trial show that dacetuzumab (SGN-40), an anti-CD40 monoclonal antibody, has some anti-myeloma effects. The best response observed during the trial was stable disease in 20 percent of patients. The study authors found that doses up to 12 mg/kg per week were well tolerated. Most side effects were mild to moderate and included fatigue, headache, nausea, and anemia. The study authors suggest that dacetuzumab may produce better…

Read the full story »
Beacon NewsFlashes – December 8, 2009
[ by Lisa Stefany | Dec 8, 2009 5:16 pm | No Comments ]
Beacon NewsFlashes – December 8, 2009

Celgene To Acquire Gloucester Pharmaceuticals And Potential Myeloma Drug Istodax – Celgene Corporation has announced its decision to merge with the privately held Gloucester Pharmaceuticals Inc. for $340 million in cash plus $300 million in future payments. The transaction is expected to be completed in early 2010. Gloucester’s first drug, Istodax (romidepsin), received FDA approval in November 2009 for the treatment of cutaneous T-cell lymphoma. Clinical trials studying the effects of Istodax and Velcade (bortezomib) in multiple…

Read the full story »
The H1N1 Swine Flu Vaccine And Multiple Myeloma: A Comprehensive Review
[ by Lisa Stefany and Gillian Losh | Nov 10, 2009 1:32 pm | One Comment ]
The H1N1 Swine Flu Vaccine And Multiple Myeloma: A Comprehensive Review

Individuals with multiple myeloma are recommended to get both the H1N1 (“swine flu”) vaccine and the seasonal flu vaccine. In particular, most myeloma patients are advised to get the shot version of the H1N1 vaccine.

About The H1N1 Flu

The H1N1 flu, also referred to as “swine flu,” has caused thousands of hospitalizations and more than 600 deaths in the United States since it was first detected in April 2009.

It is spread through person-to-person contact, often by sneezing or…

Read the full story »
Page 1 of 212»